Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning

The present project aims at comparing two conditioning regimens (FM-PTCy vs FM-ATG). The hypothesis is that one or the two regimens will lead to a 2-year cGRFS rate improvement from 30% (the cGRFS rate with FM without ATG/PTCy) to 45% (Pick-a-winner phase 2 randomized study).

Trial Details

NCT ID
NCT03852407
Phase
PHASE2
Sponsor
University of Liege
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Thymoglobulin
  • Melphalan
  • Fludarabine
  • Cyclophosphamid
Locations (sample)
  • Antwerp, Belgium|51.22047,4.40026
  • Bruges, Belgium|51.20892,3.22424
  • Brussels, Belgium|50.85045,4.34878
  • Brussels, Belgium|50.85045,4.34878
  • Brussels, Belgium|50.85045,4.34878

Key Eligibility Criteria

  • Patients V.1.1. Diseases
  • Hematological malignancies confirmed histologically:
  • AML in morphological CR or not in morphological CR but not rapidly progressing (i.e. no need to give treatments such as hydroxyurea to maintain WBC…
  • CML in CP or AP;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →